vs
亚盛医药集团（AAPG）与碧迪（BDX）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是亚盛医药集团的9147.9倍（$5.3B vs $574.1K）
亚盛医药集团是一家全球性临床阶段生物技术企业，专注于开发用于治疗癌症、慢性病毒感染及衰老相关疾病的创新靶向药物，核心研发方向为靶向细胞凋亡通路的小分子药物，业务覆盖中、美等全球市场，致力于满足未被满足的临床需求。
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
AAPG vs BDX — 直观对比
营收规模更大
BDX
是对方的9147.9倍
$574.1K
损益表 — Q4 2025 vs Q1 2026
| 指标 | | |
|---|---|---|
| 营收 | $574.1K | $5.3B |
| 净利润 | — | $382.0M |
| 毛利率 | — | 45.9% |
| 营业利润率 | — | 10.5% |
| 净利率 | — | 7.3% |
| 营收同比 | — | -0.4% |
| 净利润同比 | — | 24.0% |
| 每股收益（稀释后） | — | $1.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AAPGBDX
| Q4 25 | $574.1K | $5.3B | ||
| Q3 25 | — | $5.9B | ||
| Q2 25 | $32.6M | $5.5B | ||
| Q1 25 | — | $5.3B | ||
| Q4 24 | — | $5.2B | ||
| Q3 24 | — | $5.4B | ||
| Q2 24 | — | $5.0B | ||
| Q1 24 | — | $5.0B |
净利润AAPGBDX
| Q4 25 | — | $382.0M | ||
| Q3 25 | — | $493.0M | ||
| Q2 25 | $11.4M | $574.0M | ||
| Q1 25 | — | $308.0M | ||
| Q4 24 | — | $303.0M | ||
| Q3 24 | — | $400.0M | ||
| Q2 24 | — | $487.0M | ||
| Q1 24 | — | $537.0M |
毛利率AAPGBDX
| Q4 25 | — | 45.9% | ||
| Q3 25 | — | 47.5% | ||
| Q2 25 | 90.7% | 47.8% | ||
| Q1 25 | — | 42.8% | ||
| Q4 24 | — | 43.2% | ||
| Q3 24 | — | 45.7% | ||
| Q2 24 | — | 46.2% | ||
| Q1 24 | — | 45.7% |
营业利润率AAPGBDX
| Q4 25 | — | 10.5% | ||
| Q3 25 | — | 11.8% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 10.4% | ||
| Q4 24 | — | 8.8% | ||
| Q3 24 | — | 11.4% | ||
| Q2 24 | — | 12.1% | ||
| Q1 24 | — | 14.5% |
净利率AAPGBDX
| Q4 25 | — | 7.3% | ||
| Q3 25 | — | 8.4% | ||
| Q2 25 | — | 10.4% | ||
| Q1 25 | — | 5.8% | ||
| Q4 24 | — | 5.9% | ||
| Q3 24 | — | 7.4% | ||
| Q2 24 | — | 9.8% | ||
| Q1 24 | — | 10.6% |
每股收益（稀释后）AAPGBDX
| Q4 25 | — | $1.34 | ||
| Q3 25 | — | $1.71 | ||
| Q2 25 | — | $2.00 | ||
| Q1 25 | — | $1.07 | ||
| Q4 24 | — | $1.04 | ||
| Q3 24 | — | $1.37 | ||
| Q2 24 | — | $1.68 | ||
| Q1 24 | — | $1.85 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $740.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $25.3B |
| 总资产 | — | $54.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AAPGBDX
| Q4 25 | — | $740.0M | ||
| Q3 25 | — | $641.0M | ||
| Q2 25 | — | $735.0M | ||
| Q1 25 | — | $667.0M | ||
| Q4 24 | — | $711.0M | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $4.5B | ||
| Q1 24 | — | $2.3B |
股东权益AAPGBDX
| Q4 25 | — | $25.3B | ||
| Q3 25 | — | $25.4B | ||
| Q2 25 | — | $25.5B | ||
| Q1 25 | — | $25.2B | ||
| Q4 24 | — | $25.2B | ||
| Q3 24 | — | $25.9B | ||
| Q2 24 | — | $25.9B | ||
| Q1 24 | — | $25.6B |
总资产AAPGBDX
| Q4 25 | — | $54.8B | ||
| Q3 25 | — | $55.3B | ||
| Q2 25 | — | $54.9B | ||
| Q1 25 | — | $54.5B | ||
| Q4 24 | — | $54.7B | ||
| Q3 24 | — | $57.3B | ||
| Q2 24 | — | $55.6B | ||
| Q1 24 | — | $54.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $657.0M |
| 自由现金流经营现金流 - 资本支出 | — | $549.0M |
| 自由现金流率自由现金流/营收 | — | 10.5% |
| 资本支出强度资本支出/营收 | — | 2.1% |
| 现金转化率经营现金流/净利润 | — | 1.72× |
| 过去12个月自由现金流最近4个季度 | — | $2.6B |
8季度趋势，按日历期对齐
经营现金流AAPGBDX
| Q4 25 | — | $657.0M | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $164.0M | ||
| Q4 24 | — | $693.0M | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.3B | ||
| Q1 24 | — | $514.0M |
自由现金流AAPGBDX
| Q4 25 | — | $549.0M | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | — | $1.0B | ||
| Q1 25 | — | $35.0M | ||
| Q4 24 | — | $588.0M | ||
| Q3 24 | — | $882.0M | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $380.0M |
自由现金流率AAPGBDX
| Q4 25 | — | 10.5% | ||
| Q3 25 | — | 17.0% | ||
| Q2 25 | — | 19.0% | ||
| Q1 25 | — | 0.7% | ||
| Q4 24 | — | 11.4% | ||
| Q3 24 | — | 16.2% | ||
| Q2 24 | — | 22.4% | ||
| Q1 24 | — | 7.5% |
资本支出强度AAPGBDX
| Q4 25 | — | 2.1% | ||
| Q3 25 | — | 6.0% | ||
| Q2 25 | — | 3.2% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 2.0% | ||
| Q3 24 | — | 5.4% | ||
| Q2 24 | — | 3.6% | ||
| Q1 24 | — | 2.7% |
现金转化率AAPGBDX
| Q4 25 | — | 1.72× | ||
| Q3 25 | — | 2.75× | ||
| Q2 25 | — | 2.12× | ||
| Q1 25 | — | 0.53× | ||
| Q4 24 | — | 2.29× | ||
| Q3 24 | — | 2.94× | ||
| Q2 24 | — | 2.66× | ||
| Q1 24 | — | 0.96× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AAPG
暂无分部数据
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
